RaySearch Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

RaySearch Laboratories wird ein Gewinn- und Umsatzwachstum von 33.6% bzw. 10.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 33.7% pro Jahr wachsen soll.

Wichtige Informationen

33.6%

Wachstumsrate der Gewinne

33.7%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	21.7%
Wachstumsrate der Einnahmen	10.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	10 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

RaySearch Laboratories AB (publ) (STO:RAY B) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

May 21

One Forecaster Is Now More Bearish On RaySearch Laboratories AB (publ) (STO:RAY B) Than They Used To Be

Mar 15

Is RaySearch Laboratories (STO:RAY B) A Risky Investment?

Feb 22

Is RaySearch Laboratories (STO:RAY B) Using Debt In A Risky Way?

Nov 04

Is RaySearch Laboratories (STO:RAY B) Using Debt In A Risky Way?

Mar 30

What Kind Of Shareholders Hold The Majority In RaySearch Laboratories AB (publ)'s (STO:RAY B) Shares?

Feb 23

RaySearch Laboratories' (STO:RAY B) Shareholders Are Down 41% On Their Shares

Feb 02

Gewinn- und Umsatzwachstumsprognosen

OM:RAY B - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	1,262	184	N/A	N/A	1
12/31/2024	1,132	138	N/A	N/A	1
3/31/2024	1,049	101	251	470	N/A
12/31/2023	1,022	82	247	456	N/A
9/30/2023	987	64	256	461	N/A
6/30/2023	945	53	154	335	N/A
3/31/2023	866	22	156	349	N/A
12/31/2022	844	24	119	321	N/A
9/30/2022	768	-6	-171	233	N/A
6/30/2022	693	-38	-102	282	N/A
3/31/2022	688	-35	4	260	N/A
12/31/2021	642	-47	-17	238	N/A
9/30/2021	613	-46	36	261	N/A
6/30/2021	596	-50	67	292	N/A
3/31/2021	605	-42	144	370	N/A
12/31/2020	652	-9	106	332	N/A
9/30/2020	726	24	300	361	N/A
6/30/2020	751	43	225	334	N/A
3/31/2020	777	74	109	336	N/A
12/31/2019	742	50	108	320	N/A
9/30/2019	727	64	135	360	N/A
6/30/2019	733	85	76	295	N/A
3/31/2019	684	84	-53	173	N/A
12/31/2018	627	79	-45	178	N/A
9/30/2018	613	118	-91	105	N/A
6/30/2018	574	104	-33	153	N/A
3/31/2018	575	103	4	164	N/A
12/31/2017	585	118	N/A	147	N/A
9/30/2017	571	121	N/A	175	N/A
6/30/2017	586	151	N/A	149	N/A
3/31/2017	563	160	N/A	138	N/A
12/31/2016	531	151	N/A	121	N/A
9/30/2016	472	109	N/A	88	N/A
6/30/2016	447	94	N/A	91	N/A
3/31/2016	405	63	N/A	95	N/A
12/31/2015	398	70	N/A	111	N/A
9/30/2015	373	78	N/A	93	N/A
6/30/2015	344	76	N/A	88	N/A
3/31/2015	319	79	N/A	77	N/A
12/31/2014	285	60	N/A	50	N/A
9/30/2014	268	24	N/A	45	N/A
6/30/2014	235	-4	N/A	39	N/A
3/31/2014	211	-20	N/A	27	N/A
12/31/2013	204	-21	N/A	31	N/A
9/30/2013	191	-1	N/A	48	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RAY BDas prognostizierte Gewinnwachstum (33.6% pro Jahr) liegt über der Sparquote (1%).

Ertrag vs. Markt: RAY BDie Erträge des Unternehmens (33.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (14% pro Jahr).

Hohe Wachstumserträge: RAY BEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: RAY BDie Einnahmen des Unternehmens (10.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (1.8% pro Jahr).

Hohe Wachstumseinnahmen: RAY BDie Einnahmen des Unternehmens (10.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von RAY B in 3 Jahren voraussichtlich hoch sein wird

RaySearch Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 44% to kr195

Consensus EPS estimates increase by 10%

Price target increased by 9.5% to kr115

Price target increased to kr105

Price target decreased to kr85.00

Price target decreased to kr85.00

Recent updates

RaySearch Releases RayStation 2024B

Price target increased by 44% to kr195

RaySearch Laboratories AB (publ) Releases RayCare 2024A

Now 22% undervalued

Raysearch Laboratories AB (Publ) Apprves Ordinary Dividend for the Year 2023

RaySearch Laboratories AB (publ) (STO:RAY B) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

First quarter 2024 earnings released: EPS: kr1.07 (vs kr0.51 in 1Q 2023)

Upcoming dividend of kr2.00 per share

The Returns At RaySearch Laboratories (STO:RAY B) Aren't Growing

Raysearch to Present the Latest Advances in Raystation, Raycare and Rayintelligence At Estro 2024

Investor sentiment improves as stock rises 16%

Full year 2023 earnings: EPS misses analyst expectations

RaySearch Laboratories AB (publ) Proposes an Extra Dividend for the Year Ended December 31, 2023, Payable on May 29, 2024

RaySearch Laboratories AB (publ) to Report Fiscal Year 2024 Results on Feb 14, 2025

RaySearch Laboratories AB (publ) Releases Raystation 2024A

Consensus EPS estimates increase by 10%

Third quarter 2023 earnings released: EPS: kr0.63 (vs kr0.29 in 3Q 2022)

RaySearch Laboratories AB (publ) to Report Q2, 2024 Results on Aug 16, 2024

RaySearch Laboratories (STO:RAY B) Will Want To Turn Around Its Return Trends

RaySearch to Showcase Latest Innovations in Raystation, RayCare and RayIntelligence to Be Presented at ASTRO 2023

RaySearch Laboratories AB (Publ) to Showcase the Latest Software Innovations At Astro in San Diego, California, October 1-4

Price target increased by 9.5% to kr115

RaySearch Laboratories AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Second quarter 2023 earnings released: EPS: kr0.32 (vs kr0.58 loss in 2Q 2022)

RaySearch Laboratories AB (publ) to Report Q1, 2024 Results on May 17, 2024

RaySearch to Present the Latest Advances in Raystation, RayCare and RayIntelligence at AAPM 2023

RaySearch Laboratories AB (Publ) Announces the Release of the Latest Version of RayCare®, the Next Generation Oncology Information System

RaySearch Laboratories AB (publ) Releases Raystation 2023B

Raysearch Laboratories AB (Publ)'s RayCare in clinical use with CyberKnife at Lausanne University Hospital (CHUV) in Switzerland

Does RaySearch Laboratories (STO:RAY B) Have A Healthy Balance Sheet?

Henrik Bergentoft Leaves the Position as CFO for Raysearch

Founder recently sold kr40m worth of stock

New minor risk - Shareholder dilution

RaySearch Laboratories AB (publ) Announce to Exhibit Latest Software Innovations for Particle Therapy and BNCT at PTCOG 2023

First quarter 2023 earnings released

Director recently bought kr88k worth of stock

Founder recently sold kr1.1m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

RaySearch Laboratories AB (publ) to Report Fiscal Year 2022 Results on Feb 28, 2023

RaySearch Laboratories AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

Third quarter 2022 earnings released

Is RaySearch Laboratories (STO:RAY B) Using Too Much Debt?

High number of new directors

Raysearch Laboratories AB (Publ) Elects Günther Mårder as New Board Member

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released

Now 29% undervalued after recent price drop

Raysearch Laboratories AB (Publ) Appoints Henrik Bergentoft as Cfo, Effective from November 15, 2022

RaySearch Laboratories AB (publ) Launches RayStation 12A

RaySearch to Exhibit the Latest Software Innovations for Particle Therapy at PTCOG 2022

RaySearch Laboratories AB (publ) Releases Latest Version of RayCare

Founder recently sold kr20m worth of stock

First quarter 2022 earnings: Revenues miss analyst expectations

Price target increased to kr105

Raysearch Laboratories AB (Publ) Announces Raystation, Rayintelligence and Raycare to Be Presented At Estro 2022

Price target decreased to kr85.00

Insufficient new directors

RaySearch Laboratories AB (publ) Announces Executive Changes

One Forecaster Is Now More Bearish On RaySearch Laboratories AB (publ) (STO:RAY B) Than They Used To Be

Full year 2021 earnings: EPS and revenues miss analyst expectations

Is RaySearch Laboratories (STO:RAY B) A Risky Investment?

Founder recently sold kr5.6m worth of stock

RaySearch AB (publ) Provides Cancer Clinics with User Configurable Workflows for Radiation Therapy

RayStation 11B Brings New Features for Adaptive Workflows, Brachytherapy, and Radiation Therapy with Ions

Third quarter 2021 earnings released

Is RaySearch Laboratories (STO:RAY B) Using Debt In A Risky Way?

Price target decreased to kr85.00

RaySearch Laboratories AB (publ) to Showcase Latest Innovations, RayIntelligence and RayCare at ESTRO 2021

Second quarter 2021 earnings released